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Mechanical ventilationThe ability of pulmonary surfactant to reduce surface tension at the alveolar surface is impaired in various lung
diseases. Recent animal studies indicate that elevated levels of cholesterol within surfactant may contribute to
its inhibition. It was hypothesized that elevated cholesterol levels within surfactant inhibit human surfac-
tant biophysical function and that these effects can be reversed by surfactant protein A (SP-A). The initial
experiment examined the function of surfactant from mechanically ventilated trauma patients in the pres-
ence and absence of a cholesterol sequestering agent, methyl-β-cyclodextrin. The results demonstrated im-
proved surface activity when cholesterol was sequestered in vitro using a captive bubble surfactometer
(CBS). These results were explored further by reconstitution of surfactant with various concentrations of
cholesterol with and without SP-A, and testing of the functionality of these samples in vitro with the CBS
and in vivo using surfactant depleted rats. Overall, the results consistently demonstrated that surfactant
function was inhibited by levels of cholesterol of 10% (w/w phospholipid) but this inhibition was mitigated by
the presence of SP-A. It is concluded that cholesterol-induced surfactant inhibition can actively contribute to
physiological impairment of the lungs inmechanically ventilated patients and that SP-A levelsmay be important
to maintain surfactant function in the presence of high cholesterol within surfactant.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
In the healthy lung, pulmonary surfactant reduces the surface tension
at the alveolar surface to reduce thework of breathing andmaintain alve-
olar stability at low lung volumes [1]. This highly surface active material,
synthesized by the alveolar type II cells, is composed of amixture of phos-
pholipids, a large percentage ofwhich is dipalmitoyl-phosphatidylcholine
(DPPC), neutral lipids, themajority of which is cholesterol, and surfactant
associated proteins [2]. Once secreted into the alveolar space, surfactant
adsorbs to the air–liquid interface to form a surface ﬁlm of surfactant
lipidswhich reduces the surface tension to below5mN/m [1]. The hydro-
phobic surfactant proteins B andC (SP-B and SP-C) are involved in the for-
mation of this lipid ﬁlm [3]. Surfactant protein A (SP-A) is a large
glycoproteinwhich is part of the collectin family and is themost abundant
of the surfactant-associated proteins, representing approximately 5% oftitute E4-146 268 Grosvenor St.
x64092; fax: +1 519 646 6110.
n), ekeatin2@uwo.ca
a (L.-J. Yao), kbosma2@uwo.ca
uwo.ca (J.F. Lewis),surfactant phospholipids by weight [1,4]. It is reported to be involved in
host defensemechanismswithin the lung, regulation of surfactantmetab-
olism, as well as contributing to surface tension reduction [5,6]. Within
the alveolar space, the mixture of lipids and proteins forms highly orga-
nized lipid–protein structures known as large aggregate (LA) subtype of
surfactant. It is this subtype that is responsible for the surface activity of
surfactant [7]. With alveolar surface area changes associated with contin-
uous cycles of inhalation and exhalation, LA is converted to the small ag-
gregate (SA) subfraction, which represents the inactive form of surfactant
that is cleared from the airspace [8].
In diseased states, such as the acute respiratory distress syndrome
(ARDS), impairment of the surfactant system represents a fundamental
pathophysiologic process contributing to the observed changes in lung
function [4]. This biophysical impairment is related to changes in surfac-
tant composition as well as the inhibitory effects of substances, such as
serum proteins, that have extravasated into the airspace. This inhibition
of surfactant by serum proteins has been studied extensively and it has
been demonstrated that serum proteins directly interfere with both the
adsorption and surface tension-reducing properties of surfactant
[9–11]. Further studies have shown that this mechanism of surfactant
inhibition can bemitigated by SP-A [12]. Other alterations to the surfac-
tant system that have been linked to surfactant dysfunction in the
814 J. Qua Hiansen et al. / Biochimica et Biophysica Acta 1848 (2015) 813–820setting of ARDS include i) changes in the concentration of the phospho-
lipid components, speciﬁcally those of the active LA subfraction, ii) de-
creased concentration of surfactant associated proteins, SP-A, SP-B and
SP-C, and iii) elevated concentrations of neutral lipids, predominantly
cholesterol, relative to phospholipids within the LA subfraction of sur-
factant [4,13–15].
With respect to the latter observation, the inhibitory effects of ele-
vated cholesterol levels within pulmonary surfactant have been exten-
sively examined in vitro [16–19]. Adding high levels of cholesterol to
surfactant can inhibit surfactant function through disruption of the lat-
eral organization of the surfactant lipids in the surface ﬁlm. More re-
cently, a series of in vivo studies have demonstrated that the inhibition
of pulmonary surfactant observed in an animal model of ventilator-
induced lung injurymay occur through an elevation in the levels of cho-
lesterol within the surfactant [20,21]. It is unknown whether this phe-
nomenon occurs clinically in mechanically ventilated patients and
whether SP-A can mitigate these effects. Therefore, based on these ob-
servations we hypothesized that elevated cholesterol levels within sur-
factant can inhibit the biophysical function of human surfactant and
that these effects can be mitigated by SP-A.
2. Methods
2.1. Surfactant samples
The current study utilized three surfactant preparations: 1) LA sam-
ples obtained from a cohort of mechanically ventilated trauma patients
(described below), 2) surfactant obtained from a patient with known
pulmonary alveolar proteinosis and 3) a commercially available exoge-
nous surfactant, bovine lipid extract surfactant, BLES (BLES Biochemi-
cals Inc., London, ON, Canada). Pulmonary surfactant collected from a
patientwith pulmonary alveolar proteinosiswas obtained via therapeu-
tic whole lung lavage after obtaining informed consent. Brieﬂy, the pa-
tient was anesthetized and intubated using a dual lumen endotracheal
tube in order to ventilate each lung independently. Whole lung lavage
was then performed on the left lung and the lavage material was proc-
essed immediately to obtain surfactant LA, as described [20,22].
Surfactant from mechanically ventilated trauma patients was ob-
tained via bronchoalveolar lavage (BAL). Approval to obtain BAL sam-
ples from this patient population for research purposes was granted
by theHuman Subjects Research Ethics Board at the University ofWest-
ern Ontario and signed consent from substitute decision makers for
each patient. Patients were screened for inclusion into the study based
upon an admission diagnosis of trauma with an Injury Severity Score
(ISS) N12, resulting from a blunt mechanism of injury, on the severity
of injury, an age of 16 years or older and intubatedwith the expectation
of a need formechanical ventilation over 24 h. All aspects of clinical care,
including mechanical ventilation strategy were left to the discretion of
the attending physician. After obtaining informed consent, BAL samples
were collected within 24 h of intubation and repeat samples were col-
lected 48 h and 96 h after the ﬁrst BAL for patients who remained
intubated for that duration in order to assess changes in surfactant
over time [23]. BAL was performed in anatomical areas at the discretion
of the operator which corresponded to CT or chest X-ray areas demon-
strating normal-appearing lung. Patients received intravenous sedation
using midazolam and fentanyl and received bag-ventilation via an en-
dotracheal tube during the procedure. A bronchoscope was introduced
via the endotracheal tube andwedged in the airway of the selected seg-
ment. 50 mL of sterile saline was injected via the bronchoscope and
suctioned into a sterile container three times, for a total of 150 mL,
targeting a 50% return of lavage ﬂuid. After the BAL procedure, patients
were returned to their previous ventilator settings. Immediately follow-
ing the BAL procedure, the lavage volumewas measured and processed
as previously reported [14,22]. Total protein analysis, IL-6 measure-
ment, and surfactant isolation and measurements were performed as
previously described [20,24]. Ten lavage samples, obtained from 8patients, were determined to have sufﬁcient quantities of surfactant to
be included for the biophysical analysis to evaluate the role of
cholesterol.
2.2. Surfactant sample processing
In order to evaluate the role of cholesterol in the surfactant samples,
two complementary approaches were utilized. Human trauma patient
surfactant was depleted of cholesterol in the chamber of a captive bubble
surfactometer. For BLES and alveolar proteinosis LA samples, cholesterol
was removed from air-dried chloroform-extracted samples via acetone
precipitation. Cholesterol depletion was veriﬁed using a commercially
available free cholesterol assay kit (Wako Chemicals, Richmond, VA,
USA) and the cholesterol depleted surfactant was subsequently
reconstituted with 0, 5, 10, or 20% (w/w phospholipid) cholesterol in
chloroform, dried, and resuspended at a ﬁnal phospholipid concentration
of 5mg/mL (140mMNaCl, 10mMHepes, and2.5mMCaCl2, pH=6.9) or
10mg/mL (150mMNaCl), for in vitro and in vivo analyses respectively. A
separate set of samples was reconstituted in a similar fashionwith an ad-
ditional 5% (w/wphospholipid) of humanSP-A.HumanSP-Awaspuriﬁed
from alveolar proteinosis surfactant as previously described [25]. Brieﬂy,
alveolar proteinosis surfactant isolated from a whole lung lavage was
mixed with 1-butanol at room temperature followed by centrifugation
at 3300 g for 30min. The pellet was resuspended in 1-butanol and centri-
fuged a second time. The pellet was resuspended in a 20 mM octyl-8-D-
glucopyranoside/100mMNaCl/10mMHepes buffer (pH 7.4) and centri-
fuged at 200,000 g for 30 min. The pellet was resuspended in 5 mM TRIS,
pH 7.4, and dialysed against this bufferwith aMWcut-off 6000–8000. In-
soluble material was removed by centrifugation (200,000 g for 30 min)
and the supernatant containing SP-A stored at−70 °C [25].
2.3. In vitro analyses
The surface activity of various surfactant preparations was assessed
using a computer-controlled captive bubble surfactometer (CBS) as de-
scribed previously [19,20,26]. Brieﬂy, a surfactant sample was intro-
duced at the surface of a small bubble with the shape of the bubble
monitored for assessment of surface tension. Samples were ﬁrst ana-
lyzed for adsorption by monitoring the bubble for 5 min under a static
condition. To determine the minimum achievable surface tension, the
sample bubbles underwent dynamic compression−expansion cycles
at a rate of 20 cycles/min.Minimumsurface tensionwas recorded for cy-
cles 1, 2, 5 and 10. For samples from human trauma patients, additional
CBSmeasurementsweremade to assess the role of cholesterol. For these
measurements, the CBS chamber containing buffer with 20mMmethyl-
β-cyclodextrin (MβCD)wasused to sequester cholesterol from the sam-
ple as previously reported [17,20,27,28]. In addition to those published
studies, preliminary studies were performed to test the efﬁcacy of
the concentration of MβCD. Speciﬁcally, it was shown that an alveolar
proteinosis sample reconstituted to 20% (w/w) cholesterol reached
minimum surface tension values of 17.6 ± 1.6 mN/m, whereas the
20% (w/w) cholesterol analyzed in a buffer containing 20 mM MβCD
reached minimum surface tension values of 4.4 ± 1.3 mN/m which
was not signiﬁcantly different than samples with 5% cholesterol.
For surface ﬁlm structure analysis, Langmuir–Blodgett ﬁlms were
prepared using a Kibron μTrough SE (Helsinki, Finland) as previous-
ly described [17,29]. Brieﬂy, ﬁlms were spread by depositing drop-
lets of surfactant samples uniformly throughout the air–water
interface to an initial surface pressure of 30 mN/m (surface tension
approximately 42 mN/m). The ﬁlms were compressed and expand-
ed three times at a rate of 0.10 nm2 molecule−1 min−1 to a maximum
surface pressure of 50mN/mand a depositwas taken at the fourth com-
pression at a surface pressure of 50 mN/m (surface tension approxi-
mately 22 mN/m). Topographical atomic force microscope (AFM)
images were obtained using a Nanoscope III scanning force multimode
Table 1
Patient characteristics.
Patient Age M/F PO2/FIO2
(mm Hg)
Ventilation
mode
PEEP Time of BAL after
intubation (h)
BAL volume
(mL)
Total surfactant
(μg PL)
% large
aggregates
Protein
(mg/mL)
IL-6
(pg/mL)
1 72 F 270 SIMV/PSV 5 117 46 317 79 0.3 52
2 84 M 265 PSV 5 61 12 1480 72 4.5 710
3A 64 M 222 PSV 10 71 18 1860 77 2.3 254
3B 280 AC/PC 8 209 28 1076 93 0.8 44
4 38 M 89 SIMV 10 21 14 1054 71 1.2 1104
5 30 M 130 AC 5 60 27 1939 75 0.6 246
6 82 M 144 PSV 10 65 23 2363 71 3.1 2668
7 20 M 383 AC 5 15 27 5353 70 2.6 2133
8A 22 F 62 AC 8 12 25 2416 70 2.5 4314
8B 71 AC 12 65 27 2677 80 2.3 2131
SIMV synchronized intermittent mandatory ventilation
PSV pressure support ventilation
ACV assist control ventilation
PCV pressure control ventilation
PL phospholipid.
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was performed using the Nanoscope III software (version 5.12r3).
2.4. In vivo analyses
To analyze surfactant function in vivo, a lung lavage model of surfac-
tant depletion in rats was utilized as previously reported [24]. All proce-
dures were approved by the animal use subcommittee at the University
of Western Ontario in agreement with the guidelines of the Canadian
Council of Animal Care. Brieﬂy, rats were anesthetized, connected to a
mechanical ventilator (8 mL/kg tidal volume (Vt), respiratory rate
(RR) of 54–58 breaths per minute (bpm), 5 cm H2O positive end-
expiratory pressure (PEEP) and a fraction of inspired oxygen (FiO2) of
1.0.) anddepleted of endogenous surfactant pools by repetitive saline la-
vage. After surfactant depletion, indicated by a reduction in PO2/FiO2
values to below 150 mm Hg, rats were randomized to receive either
an intratracheal instillation of i) 1 mL/kg bodyweight (BW) bolus of
air, ii) 1 mL/kg BW volume of surfactant (10 mg phospholipid/mL)
with 5% (w/w) cholesterol (n = 6), iii) surfactant with 5% cholesterol
(w/w)+ 5% (w/w) SP-A (n=7), iv) surfactantwith 20% (w/w) choles-
terol (n = 6) or v) surfactant with 20% (w/w) cholesterol + 5% (w/w)
SP-A (n = 6). Rats were then ventilated for 120 min using ventilation
parameters as described above. Airway pressure, hemodynamics, and
blood gas measurements were recorded every 15 min. Following the
2 h of ventilation, animals were administered with sodium pentobarbi-
tal (75 mg/kg BW) and exsanguinated by transection of the descending
aorta. A whole-lung lavage was performed, processed and analyzed as
previously described [21,22].
2.5. Statistical analysis
Analysis of surfactant function for samples frommechanically venti-
lated trauma patients was performed using a paired t-test. Remaining
statistical analyses utilized a two-way ANOVA followed by Tukey's
post-hoc test. Means are reported ± SEM. Values were considered sig-
niﬁcantly different at a probability value b 0.05.
3. Results
3.1. In vitro analysis of surfactant from mechanically ventilated trauma
patients
The ﬁrst experiment analyzed ten BAL samples obtained from eight
mechanically ventilated trauma patients. Clinical, physiological and BAL
data from these 8 trauma patients are shown in Table 1. For two of the
patients (patients #3 and #8) two separate BAL samples obtained atdifferent time points were analyzed. As shown in Table 1, this patient
population ranged in age from 24 to 84 years and had oxygenation
and compliance values that varied signiﬁcantly. In addition, BAL sam-
ples were obtained at various times after intubation, ranging from 12
to 209 h. Amounts of surfactant recovered in BAL ﬂuid varied among pa-
tients, however, in all patients the majority of surfactant recovered was
in the LA form (average 75.8 ± 7.1%). The concentration of total protein
and the inﬂammatory cytokine, interleukin-6, also variedwidely among
patients.
Aliquots of the LA samples obtained from patients were analyzed for
biophysical activity on a CBS with and without the cholesterol seques-
tering agent, MβCD. The observed surface tension values for two differ-
ent time points after adsorption (60 and 300 s) are shown in Fig. 1.
Surface tension values were signiﬁcantly lower in samples incubated
with MβCD as compared to the controls at both 60 and 300 s. Fig. 2
shows minimum surface tension values from all 10 samples for 4 dy-
namic compression–expansion cycles. All samples achieved lowermin-
imum surface tensions in the presence ofMβCDas compared towithout
MβCD. This effect was statistically signiﬁcant at each cycle analyzed.
3.2. In vitro analysis of the effect of SP-A on cholesterol mediated inhibition
of human alveolar proteinosis surfactant
Fig. 3 shows the effect of increasing concentrations of cholesterol on
the surface tension reducing properties of surfactant following adsorption
of human alveolar proteinosis surfactant in the absence (A) or presence of
SP-A (B). Surfactant containing 0% and 5% (w/w) cholesterol, without SP-
A, demonstrated rapid adsorption reaching equilibrium surface tension
values of approximately 23 mN/m in 30 s. Samples containing 10% and
20% (w/w) cholesterol had slower adsorption compared to the 0 and
5% (w/w) cholesterol samples. This difference was statistically signiﬁcant
from5 to 60 s for 10% (w/w) cholesterol, and from5 to 30 s for 20% (w/w)
cholesterol, as compared to the 0% (w/w) cholesterol sample.
For samples containing 5% (w/w) SP-A (Fig. 3B) there were no sig-
niﬁcant differences among the samples reconstituted with different
levels of cholesterol. Comparisons between surfactant samples contain-
ing similar levels of cholesterol with or without SP-A showed that sam-
ples containing 10% (w/w) cholesterol + 5% (w/w) SP-A had a
signiﬁcantly reduced surface tension from0 to 60 s as compared to sam-
pleswith 10% (w/w) cholesterolwithout SP-A. Similarly, surfactant con-
taining 20% (w/w) cholesterol with 5% (w/w) SP-A showed a
signiﬁcantly lower surface tension from time points 10 to 60 s as com-
pared to surfactant containing 20% (w/w) cholesterol without SP-A.
The minimum achievable surface tension of the alveolar proteinosis
surfactant samples over the course of ten dynamic expansion–compres-
sion cycles is shown in Fig. 4. Within each surfactant group, there were
Fig. 1. Effect of MβCD on in vitro adsorption of patient surfactant samples. Surface tension
after adsorption of surfactant isolated from individualmechanically ventilated trauma pa-
tients with and without incubation with MβCD. * = p b 0.05 LA +MβCD versus LA.
A
B
Fig. 3. Effect of SP-A and cholesterol on surfactant adsorption in vitro. Surface ten-
sion (mN/m) during 300 s of initial adsorption of human alveolar proteinosis sur-
factant reconstituted with different levels of cholesterol without (A) and with
(B) 5% (w/w) SP-A, as indicated in the legend. Values are reported as mean ± stan-
dard error, a = p b 0.05 versus 0% (w/w) cholesterol, b = p b 0.05 vs. 5% (w/w)
cholesterol, # = p b 0.05 versus 10% (w/w) cholesterol without SP-A, and * =
p b 0.05 vs. 20% (w/w) cholesterol without SP-A, n = 3/group.
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pansion–compression cycles. Samples with 10% (w/w) cholesterol and
20% (w/w) cholesterol, without SP-A (Fig. 4A), had signiﬁcantly higher
surface tensions than the 0% (w/w) cholesterol and 5% (w/w) cholesterol
groups throughout all cycles. Among alveolar proteinosis surfactant sam-
ples reconstituted with SP-A (Fig. 4B), there were no signiﬁcant differ-
ences in minimum surface tension between groups containing 0, 5 or
10% (w/w) cholesterol throughout all compression–expansion cycles.
Surfactant containing 20% (w/w) cholesterol + 5% (w/w) SP-A had a sig-
niﬁcantly higher minimum surface tension than all other surfactant
groups reconstitutedwith 5% (w/w) SP-A. Additionally, therewere signif-
icant differences between groups treated with SP-A and those without.
Speciﬁcally, surfactant with 5% (w/w) cholesterol + 5% (w/w) SP-A hadFig. 2. Effect of MβCD onminimum surface tension during compression–expansion cycles of patient surfactant. Minimum surface tensions of surfactant isolated from individual mechan-
ically ventilated trauma patients with and without incubation with MβCD, during various dynamic compression–expansion cycles. * = p b 0.05 LA +MβCD versus LA.
AB
Fig. 4. Effect of SP-A and cholesterol onminimum surface tension during repeated compres-
sion–expansion cycles in vitro. Minimum surface tension (mN/m) of human alveolar
proteinosis surfactant reconstituted with different levels of cholesterol without (A) and
with (B) 5% (w/w) SP-A during various dynamic compression–expansion cycles. Values are
reported as mean ± standard error, a = p b 0.05 vs. 0% (w/w) cholesterol, b = p b 0.05 vs.
5% (w/w) cholesterol, c = p b 0.05 vs. 10% (w/w) cholesterol and * = p b 0.05 versus same
sample without SP-A, n = 3/group.
Fig. 5. In vivo activity of surfactants with various amounts of cholesterol and SP-A. Arterial
oxygenation content (mm Hg) after endogenous surfactant depletion and administration
of BLES with various amounts of cholesterol ± 5% (w/w) SP-A and 120min of mechanical
ventilation. Values aremeans± SE, n= 6–7/group, a= p b 0.05 vs. 5% (w/w) cholesterol,
b = p b 0.05 vs. 5% (w/w) cholesterol + 5% (w/w) SP-A, and c = p b 0.05 vs. 20% (w/w)
cholesterol + 5% (w/w) SP-A.
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compared to surfactant with 5% (w/w) cholesterol without SP-A. Similar-
ly, surfactant with 10 and 20% (w/w) cholesterol + 5% (w/w) SP-A had
signiﬁcantly lower minimum surface tensions when compared to similar
samples lacking SP-A throughout all expansion–compression cycles.
3.3. In vivo analysis of SP-A on cholesterol mediated inhibition of exogenous
surfactant
Surfactant depleted rats were treated with exogenous surfactant,
BLES, containing 5 or 20% (w/w) cholesterol, with and without 5%
(w/w) SP-A to determine the physiological effects of excess choles-
terol in the presence and absence of SP-A in surfactant. Fig. 5 depicts
arterial oxygenation (PaO2) over the course of 120 min of mechani-
cal ventilation. In animals receiving BLES plus 5% (w/w) cholesterol,
PaO2 values were signiﬁcantly increased 15 min after surfactant ad-
ministration compared to animals receiving an air bolus control
and remained signiﬁcantly higher throughout the remaining
120 min of mechanical ventilation. Rats administered exogenous
surfactant containing 20% (w/w) cholesterol had oxygenation values
that were not signiﬁcantly different than animals treated with an air
bolus alone over the entire course of mechanical ventilation. In the
two groups receiving exogenous surfactant containing either 5% or
20% (w/w) cholesterol with SP-A, oxygenation was signiﬁcantly in-
creased 15 min after administration and remained signiﬁcantly
higher oxygenation throughout ventilation as compared to rats
treated with an air bolus alone. Analysis of collected surfactantfrom lavage after exogenous surfactant administration and mechan-
ical ventilation showed that there were no signiﬁcant differences in
the pool sizes of either the total amount or the LA and SA sub-
fractions of surfactant, regardless of cholesterol or SP-A content of
the surfactant administered (Fig. 6).
3.4. Surface ﬁlm analysis of cholesterol containing surfactant with and
without SP-A
In order to further investigate the effects of cholesterol and SP-A on
surfactant function, samples of BLES similar to those used in the above
in vivo experiments were examined by AFM. Based on previous studies
demonstrating that cholesterol impairs functional surfactant multilayer
formation, samples were analyzed at a surface tension of approximately
22 mN/m at which, in functional surfactant, multilayers are observed
[29]. The results of samples containing 5% (w/w) cholesterol (Fig. 7A)
show higher (lighter) areas surrounding the darker “wells”with height
analysis demonstrating that these higher areas are 1 to 3 bilayers in
thickness. The addition of 5% (w/w) SP-A led to a similar pattern, with
bi- and multi-layers (Fig. 7B) surrounding the lower, darker, areas.
The pattern of samples with 20% (w/w) cholesterol was noticeably dif-
ferent, with higher, multiple layer ﬁlm areas being limited to a small
number of sites. Although 5% (w/w) SP-A added to the 20% (w/w) cho-
lesterol sample did not completely restore surface ﬁlm morphology to-
wards the structures observed for 5% (w/w) cholesterol containing
sample, more widely distributed areas of multilayers were observed.
4. Discussion
The current study tested the hypothesis that elevated cholesterol
levels within surfactant can inhibit the surface tension reducing func-
tion of human surfactant and that these effects can be mitigated by
SP-A. Our initial experiment focused onmechanically ventilated trauma
patients. Despite the heterogeneous nature of this cohort of patients, in-
cluding age, ventilation parameters, oxygenation parameters and
timing of lavage procedure subsequent to the onset of mechanical ven-
tilation, a consistent improvement in surfactant function was observed
across all 10 samples with the addition of MβCD. This information was
AB
C
Fig. 6. Surfactant pool sizes following120minofmechanical ventilation. Surfactant pool sizes
(mg phospholipid/kg BW) of rats depleted of endogenous surfactant followed by the admin-
istration of BLES with various amounts of cholesterol ± 5% (w/w) SP-A and 120 min of me-
chanical ventilation. Measurement of (A) total surfactant (B) large and (C) small aggregate
pool sizes. Values are means ± SE, n = 6–7/group, a = p b 0.05 vs. air group.
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functionwas inhibitedwhen reconstitutedwithhigh levels of cholester-
ol in vitro. Furthermore, it was also demonstrated that a clinically rele-
vant exogenous surfactant preparation, BLES, had impaired function in
the presence of excess cholesterol contentwhen administered to surfac-
tant deﬁcient animals. Togetherwith published evidence of cholesterol-
mediated inhibition of surfactant in mechanically ventilated animals
[20,21], these results support the conclusion that cholesterol-induced
surfactant inhibition can actively contribute to physiological impair-
ment of the lungs in mechanically ventilated patients.
To further explore the concept of cholesterol-mediated surfactant
inhibition, we investigated the role of SP-A on this process. Using
in vitro and in vivo approaches, the results provided evidence for a ben-
eﬁcial effect of 5% (w/w) SP-A inmitigating the inhibitory effects of cho-
lesterol on surfactant function. Beneﬁcial effects of SP-A in the context
of surfactant dysfunction have also been demonstrated in other studies
evaluatingmechanisms of surfactant inhibition. For example, Cockshutt
et al. demonstrated that reconstitution of SP-A in surfactant mitigated
the inhibitory effect of serum-proteins on surfactant dysfunction [12].
Similarly, SP-A mitigated surfactant inhibition mediated by oxidized
phospholipids and meconium in the context of neonatal aspiration
[24,30,31]. Interestingly, naive mice deﬁcient in SP-A possess normal
lung and surfactant function under basal conditions [32,33]. Together,
these ﬁndings suggest that although SP-A may not have an essential
role in baseline surfactant function, it may serve an important role in
improving or maintaining biophysical function of surfactant in the set-
ting of compromised host surfactant function.The speciﬁc biophysical mechanism(s) of cholesterol-mediated
surfactant inhibition have been previously studied in vitro [16–19].
Although various molecular models of surfactant function have
been proposed, the lateral organization of the surfactant lipids at
high surface tensions coupled with the formation of lipid multilayers
during compression represent the basis of the majority of proposed
mechanisms [11,34]. Ultimately, a ﬁlm of lipids remaining in a
“solid” state capable of reaching low surface tensions appears to be
important. Cholesterol can form a complex with some of the saturat-
ed phospholipids, mainly DPPC in the more solid area of the ﬁlm. The
inhibitory effect of elevated cholesterol on surfactant function ap-
pears to be through increasing the ﬁlm ﬂuidity, which occurs when
the excess cholesterol interacts with some of the more “ﬂuid” unsat-
urated phospholipids within the ﬁlm. This was demonstrated by
Gunasekara and colleagues [35] who showed that adding 20% choles-
terol to BLES inhibited the function of this surfactant preparation, but
that this inhibitory effect could be counteracted by adding 40% DPPC,
thereby restoring the DPPC-cholesterol ratio. More direct evidence of
a role forﬁlm ﬂuidity has been obtained usingAFM.Using BLESwith ap-
proximately 10% (w/w) cholesterol it was demonstrated that at high
surface tension the lateral structure of the ﬁlm exhibited altered forma-
tion of liquid expanded (ﬂuid) and liquid condensed (solid) domains
[17]. We have conﬁrmed these observations with the alveolar
proteinosis samples utilized in the current study (data not shown).
Leonenko and colleagues further investigated the effects of ﬁlm struc-
ture by AFM by examining the structure at low surface tensions [18].
These studies demonstrated that elevated cholesterol led to impairment
in the formation of multilayers during compression. Together these
studies suggest that the major impact of cholesterol is on increasing
the ﬂuidity of the ﬁlm, thereby resulting in collapse rather than multi-
layer formation during lateral compression.
In view of this mechanism of cholesterol inhibition, it is interesting
to speculate on the mechanism by which SP-A can counteract this inhi-
bition. Considering that evidence in the literature has demonstrated
that SP-A can also counteract protein inhibition of surfactant by various
serum proteins and inhibition of surfactant due to oxidation [12,30,31],
we propose that this activity of SP-A likely reﬂects a common property
of this protein, rather than uniquemechanisms for each different inhib-
itors. The suggested mechanisms for counteracting these latter forms of
inhibition have been through enhance adsorption, formation of tubular
myelin and stabilizing multilayer formation [29,36,37]. Our results for
cholesterol mediated inhibition support this latter mechanism as AFM
analysis showed that SP-A may stabilize multilayer formation even in
the presence of a more ﬂuid ﬁlm due to high cholesterol, although this
effect was not a complete reversal (Fig. 7). Further studies are required
to speciﬁcally investigate the process by which SP-A enhances surfac-
tant function in the presence of various inhibitors.
The clinical relevance of our study was shown by the analysis of
samples obtained from mechanically ventilated patients. The majority
of previous studies investigating the mechanisms leading to the inhibi-
tion of pulmonary surfactant function in humans have focused on well-
deﬁnedpatient populations, such as thosewithmild or severe ARDS [13,
14,38]. Those patients have, by deﬁnition, lung dysfunction including
low blood oxygenation and reduced lung compliance. It is notable that
despite our broad inclusion of trauma patients undergoing prolonged
ventilation, cholesterol-mediated surfactant inhibition was consistently
observed. This result suggests that prolonged ventilation itself may be a
contributing factor to the cholesterol mediated surfactant dysfunction.
Although not studied in a heterogeneous population of mechanically
ventilated patients, there is strong evidence frommechanically ventilat-
ed patients with ARDS that SP-A levels decrease in this setting [4,13,39].
For example, Schmidt and colleagues showed levels of SP-A changing
from 4.1% (w/w) in healthy volunteers to 2.6% in patients with ARDS
within the ﬁrst 24 h of diagnosis [4]. In general, considering the wide-
spread use of mechanical ventilation among a broad population of pa-
tients in intensive care units, these ﬁndings offer further insight into
Fig. 7. AFM topographic images of surfactant with various amounts of cholesterol and SP-A. Typical AFM topographic images of BLES ﬁlms+ 5% (w/w) cholesterol (A) (−) SP-A, (B) (+)
SP-A or 20% (w/w) cholesterol, (C) (−) SP-A, and (D) (+) SP-A deposited by the Langmuir–Blodgett technique. Each ﬁlmwas subjected to 3 full cycles of compression to surface tension
approx. 22 mN/m and expansion to maximum area and deposits were taken on the fourth compression. All scanned areas are 20 × 20 μm2.
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cations for an even broader population of patients.
Although not the primary focus of this study, the surfactant
subfractions from samples obtained from ventilated and surfactant de-
pleted rats were also examined. This analysis allowed a preliminary as-
sessment to determine if elevated levels of cholesterol with surfactant,
with and without SP-A, were metabolized differently within the air-
space. Previous in vivo experiments have suggested that SP-A promotes
the re-uptake of surfactant into type-II alveolar cells and may modulate
the secretion of surfactant [40,41]. We observed a trend of lower recov-
ered surfactant pool sizes from animals administered surfactant
reconstituted with 5% (w/w) SP-A, as compared to animals treated
with surfactant lacking the protein, indicating that SP-Amay have a reg-
ulatory role on surfactant metabolismwithin the lungs. Interestingly, to
our knowledge, there is no information available on the effect of choles-
terol on the alveolarmetabolism of surfactant pool sizes or subfractions.
Based on the lack of differences in pool sizes recovered in our experi-
ment between the animals receiving surfactant with either 5 or 20%
(w/w) cholesterol, we propose that cholesterol does not impact alveolar
metabolism directly.
Overall, although our study provides strong evidence for the role
of surfactant inhibition by cholesterol and mitigation by SP-A, sever-
al limitations should be noted. With regard to the data from ventilat-
ed patients (Fig. 1, 2), the small amount of surfactant recovered from
BAL samples precluded direct measurements of cholesterol concen-
trations within individual samples or analysis of these samples in
the presence of SP-A. These are considered future studies. Addition-
ally, the MβCD utilized to sequester cholesterol may be relatively
non-speciﬁc and binding of other inhibitory components cannot be
excluded. However, three lines of evidence support that the major
effect of MβCD is through cholesterol sequestration. First, in our con-
trol experiments with alveolar proteinosis sample containing 20%
(w/w) cholesterol, we demonstrated that MβCD could restore the
function of the surfactant. Second, in published studies with ratsurfactant containing 13% (w/w) cholesterol, we measured reduced
cholesterol values (to approximately 2%) following incubation with
MβCD which was associated with improved activity; furthermore,
restoring the cholesterol levels to its original 13% (w/w) value result-
ed in inhibition similar to the unaltered sample [20]. Third, it was
demonstrated that the addition of cholesterol to BLES leads to a
change in ﬁlm structure by AFM which can be reversed with treat-
ment with MβCD [17]. Finally, our study focused only on SP-A in
the context of cholesterol inhibition. The role of the hydrophobic
surfactant proteins, SP-B and SP-C, in the activity of surfactant with
high cholesterol also warrants further investigation.
In conclusion, the current study built upon previous in vitro and
in vivo studies by demonstrating that cholesterol mediated surfactant
dysfunction occurs in a cohort of mechanically ventilated patients.
Moreover, we show that SP-A can mitigate these effects in both in vivo
and in vitro assays. Further studies are required to determine whether
cholesterol inhibition of surfactant may be used clinically to guide the
prognosis or treatment in individuals requiring prolonged mechanical
ventilation.Acknowledgements
The authors like to thank BLES Biochemicals Inc. for generously
providing BLES. The authors also acknowledge Fred Possmayer for
the helpful discussions, Dr Matthias Amrein for the help in establish-
ing the captive bubble surfactometer technique, Lynda McCaig for
the help with the animal experimentation, Valeria Puntorieri, Bran-
don Banaschewski, Julianna Decuzzi and Scott Milos for proofreading
the manuscript, and all the clinical staff involved in obtaining BAL
samples from trauma patients. This research was funded by operat-
ing grants from the Canadian Institutes of Health Research and the
Ontario Thoracic Society, as well as local funding from the program
of Experimental Medicine and Western University.
820 J. Qua Hiansen et al. / Biochimica et Biophysica Acta 1848 (2015) 813–820References
[1] J. Goerke, Pulmonary surfactant: functions and molecular composition, Biochim.
Biophys. Acta 1408 (1998) 79–89.
[2] L.M.G. Van Golde, J.J. Batenburg, B. Robertson, The pulmonary surfactant system,
News Physiol. Sci. 9 (1994) 13–20.
[3] S.H. Yu, F. Possmayer, Comparative studies on the biophysical activities of the low-
molecular-weight hydrophobic proteins puriﬁed from bovine pulmonary surfactant,
Biochim. Biophys. Acta 961 (1988) 337–350.
[4] R. Schmidt, P. Markart, C. Ruppert, M. Wygrecka, T. Kuchenbuch, D. Walmrath, W.
Seeger, A. Guenther, Time-dependent changes in pulmonary surfactant function
and composition in acute respiratory distress syndrome due to pneumonia or aspi-
ration, 11 (2007) 1–11.
[5] P.S. Kingma, J.A.Whitsett, In defense of the lung: surfactant protein A and surfactant
protein D, Curr. Opin. Pharmacol. 6 (2006) 277–283.
[6] J.R. Wright, S. Hawgood, Pulmonary surfactant metabolism, Clin. Chest Med. 10
(1989) 83–93.
[7] A.M. Brackenbury, J.L. Malloy, L.A. McCaig, L.-J. Yao, R.A.W. Veldhuizen, J.F. Lewis,
Evaluation of alveolar surfactant aggregates in vitro and in vivo, Eur. Respir. J. 19
(2002) 41–46.
[8] N.J. Gross, Extracellular metabolism of pulmonary surfactant: the role of a new ser-
ine protease, Annu. Rev. Physiol. 57 (1995) 135–150.
[9] B.A. Holm, A.R. Venkitaraman, G. Enhorning, R.H. Notter, Biophysical inhibition of
synthetic lung surfactants, Chem. Phys. Lipids 52 (1990) 243–250.
[10] W. Seeger, G. Stohr, H.R. Wolf, H. Neuhof, Alteration of surfactant function due to
protein leakage: special interaction with ﬁbrin monomer, J. Appl. Physiol. 58
(1985) 326–338.
[11] Y.Y. Zuo, R.A.W. Veldhuizen, a W. Neumann, N.O. Petersen, F. Possmayer, Current
perspectives in pulmonary surfactant — inhibition, enhancement and evaluation,
Biochim. Biophys. Acta 1778 (2008) 1947–1977.
[12] A.M. Cockshutt, J. Weitz, F. Possmayer, Pulmonary surfactant-associated protein A
enhances the surface activity of lipid extract surfactant and reverses inhibition by
blood proteins in vitro, Biochemistry 29 (1990) 8424–8429.
[13] T.J. Gregory, W.J. Longmore, M.A. Moxley, J.A. Whitsett, C.R. Reed, A.A. Fowler, R.J.
Maunder, C. Crim, T.M. Hyers, Surfactant chemical composition and biophysical ac-
tivity in acute respiratory distress syndrome, J. Clin. Invest. 88 (1991) 1976–1981.
[14] R.A. Veldhuizen, L.A. McCaig, T. Akino, J.F. Lewis, Pulmonary surfactant subfractions
in patients with the acute respiratory distress syndrome, Am. J. Respir. Crit. Care
Med. 152 (1995) 1867–1871.
[15] P. Markart, C. Ruppert, M. Wygrecka, T. Colaris, B. Dahal, D. Walmrath, H. Harbach, J.
Wilhelm, W. Seeger, R. Schmidt, A. Guenther, Patients with ARDS show improve-
ment but not normalisation of alveolar surface activity with surfactant treatment:
putative role of neutral lipids, Thorax 62 (2007) 588–594.
[16] R.V. Diemel, M.M. Snel, L.M. Van Golde, G. Putz, H.P. Haagsman, J.J. Batenburg, Effects
of cholesterol on surface activity and surface topography of spread surfactant ﬁlms,
Biochemistry 41 (2002) 15007–15016.
[17] E. Keating, L. Rahman, J. Francis, A. Petersen, F. Possmayer, R. Veldhuizen, N.O.
Petersen, Effect of cholesterol on the biophysical and physiological properties of a
clinical pulmonary surfactant, Biophys. J. 93 (2007) 1391–1401.
[18] Z. Leonenko, S. Gill, S. Baoukina, L.Monticelli, J. Doehner, F. Felderer,M. Rodenstein, L.M.
Eng,M. Amrein, L. Gunasekara, An elevated level of cholesterol impairs self-assembly of
pulmonary surfactant into a functional ﬁlm, Biophys. J. 93 (2007) 674–683.
[19] L. Gunasekara, W.M. Schoel, S. Schurch, M.W. Amrein, S. Schürch, A comparative
study of mechanisms of surfactant inhibition, Biochim. Biophys. Acta 1778 (2008)
433–444.
[20] D. Vockeroth, L. Gunasekara, M. Amrein, F. Possmayer, J.F. Lewis, R.A. Veldhuizen,
The role of cholesterol in the biophysical dysfunction of surfactant in ventilator in-
duced lung injury, Am. J. Physiol. Lung Cell. Mol. Physiol. 298 (2010) L117–L125.
[21] A.A. Maruscak, D.W. Vockeroth, B. Girardi, T. Sheikh, F. Possmayer, J.F. Lewis, R.A.W.
Veldhuizen, Alterations to surfactant precede physiological deterioration during
high tidal volume ventilation, Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008)
L974–L983.[22] T.C. Bailey, A.A. Maruscak, E.L. Martin, A.R. Forbes, A. Petersen, L.A. McCaig, L.-J.J. Yao,
J.F. Lewis, R.A.W. Veldhuizen, The effects of long-term conventional mechanical ven-
tilation on the lungs of adult rats, Crit. Care Med. 36 (2008) 2381–2387.
[23] K. Bosma, R. Kao, T. Charyk-Stewart, R.A.W. Veldhuizen, L. McCaig, L.J. Yao, J. Lewis,
Bronchoalveolar lavage analysis in mechanically ventilated trauma patients, Am. J.
Respir. Crit. Care Med. 169 (2004) A682.
[24] T.C. Bailey, K. a Da Silva, J.F. Lewis, K. Rodriguez-Capote, F. Possmayer, R.A.W.
Veldhuizen, Physiological and inﬂammatory response to instillation of an oxidized
surfactant in a rat model of surfactant deﬁciency, J. Appl. Physiol. 96 (2004)
1674–1680.
[25] J.S. Haurum, S. Thiel, H.P. Haagsman, S.B. Laursen, B. Larsen, J.C. Jensenius, Studies on
the carbohydrate-binding characteristics of human pulmonary surfactant-
associated protein A and comparison with two other collectins: mannan-binding
protein and conglutinin, Biochem. J. 293 (1993) 873–878.
[26] S. Schurch, H. Bachofen, J. Goerke, F. Possmayer, A captive bubble method repro-
duces the in situ behavior of lung surfactant monolayers, J. Appl. Physiol. 67
(1989) 2389–2396.
[27] L.C. Gunasekara, R.M. Pratt, W.M. Schoel, S. Gosche, E.J. Prenner, M.W. Amrein,
Methyl-beta-cyclodextrin restores the structure and function of pulmonary surfac-
tant ﬁlms impaired by cholesterol, Biochim. Biophys. Acta 1798 (2009) 986–994.
[28] H. Ohvo, J.P. Slotte, Cyclodextrin-mediated removal of sterols from monolayers: ef-
fects of sterol structure and phospholipids on desorption rate, Biochemistry 35
(1996) 8018–8024.
[29] Y.Y. Zuo, S.M. Tadayyon, E. Keating, L. Zhao, R.A. Veldhuizen, N.O. Petersen, M.W.
Amrein, F. Possmayer, Atomic force microscopy studies of functional and dysfunc-
tional pulmonary surfactant ﬁlms, II: albumin-inhibited pulmonary surfactant
ﬁlms and the effect of SP-A, Biophys. J. 95 (2008) 2779–2791.
[30] K. Rodriguez Capote, F.X. McCormack, F. Possmayer, Pulmonary surfactant protein-A
(SP-A) restores the surface properties of surfactant after oxidation by a mechanism
that requires the Cys6 interchain disulﬁde bond and the phospholipid binding do-
main, J. Biol. Chem. 278 (2003) 20461–20474.
[31] B. Sun, T. Curstedt, G. Lindgren, B. Franzén, A.A. Alaiya, A. Čalkovska, B. Robertson,
Biophysical and physiological properties of a modiﬁed surfactant enriched with a
surfactant protein A, Eur. Respir. J. 10 (1997) 1967–1974.
[32] T.R. Korfhagen, A.M. LeVine, J.A. Whitsett, Surfactant protein A (SP-A) gene targeted
mice, Biochim. Biophys. Acta 1408 (1998) 296–302.
[33] M. Ikegami, T.R. Korfhagen, J.A. Whitsett, M.D. Bruno, S.E. Wert, K. Wada, A.H. Jobe,
Characteristics of surfactant from SP-A-deﬁcient mice, Am. J. Physiol. 275 (1998)
L247–L254.
[34] E. Keating, Y.Y. Zuo, S.M. Tadayyon, N.O. Petersen, F. Possmayer, R. a W. Veldhuizen,
A modiﬁed squeeze-out mechanism for generating high surface pressures with pul-
monary surfactant, Biochim. Biophys. Acta 1818 (2012) 1225–1234.
[35] L. Gunasekara, S. Schurch, W.M. Schoel, K. Nag, Z. Leonenko, M. Haufs, M. Amrein, S.
Schürch, S. Schu, Pulmonary surfactant function is abolished by an elevated propor-
tion of cholesterol, Biochim. Biophys. Acta 1737 (2005) 27–35.
[36] S. Schurch, F. Possmayer, S. Cheng, A.M. Cockshutt, Pulmonary SP-A enhances ad-
sorption and appears to induce surface sorting of lipid extract surfactant, Am. J.
Physiol. 263 (1992) L210–L218.
[37] W.F. Voorhout, T. Veenendaal, H.P. Haagsman, A.J. Verkleij, L.M. Van Golde, H.J.
Geuze, Surfactant protein A is localized at the corners of the pulmonary tubular my-
elin lattice, J. Histochem. Cytochem. 39 (1991) 1331–1336.
[38] I. Frerking, A. Gunther, W. Seeger, U. Pison, a Günther, Pulmonary surfactant: func-
tions, abnormalities and therapeutic options, Intensive Care Med. 27 (2001)
1699–1717.
[39] M. Hallman, P. Maasilta, I. Sipila, J. Tahvanainen, Composition and function of pul-
monary surfactant in adult respiratory distress syndrome, Eur. Respir. J. Suppl. 3
(1989) 104s–108s.
[40] J.R. Wright, L.G. Dobbs, Regulation of pulmonary surfactant secretion and clearance,
Annu. Rev. Physiol. 53 (1991) 395–414.
[41] S.R. Bates, C. Dodia, J.-Q. Tao, A.B. Fisher, Surfactant protein-A plays an important
role in lung surfactant clearance: evidence using the surfactant protein-A gene-
targeted mouse, Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008) L325–L333.
